APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This trial is a phase 1/1b study to evaluate the safety, efficacy, and tolerability of
APX005M in combination with nivolumab and cabiralizumab.
The phase 1 dose escalation portion of the study will enroll patients with advanced solid
tumors melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) in 6
cohorts to determine the recommended phase II dose (RP2D) of APX005M.
The phase 1b dose expansion portion will study the triple drug combination separately in the
three disease cohorts: melanoma, NSCLC, and RCC.